White Pine Capital LLC bought a new position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 147,720 shares of the medical research company’s stock, valued at approximately $2,712,000.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Allworth Financial LP lifted its position in shares of NeoGenomics by 53.9% during the third quarter. Allworth Financial LP now owns 6,361 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 2,229 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in NeoGenomics by 51.7% during the third quarter. Maryland State Retirement & Pension System now owns 28,451 shares of the medical research company’s stock worth $522,000 after purchasing an additional 9,700 shares during the last quarter. Lisanti Capital Growth LLC bought a new stake in NeoGenomics in the 3rd quarter worth about $1,362,000. Jacobi Capital Management LLC bought a new stake in NeoGenomics in the 3rd quarter worth about $37,000. Finally, Illinois Municipal Retirement Fund grew its position in NeoGenomics by 6.1% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 67,830 shares of the medical research company’s stock worth $1,245,000 after purchasing an additional 3,915 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.
NeoGenomics Price Performance
Shares of NASDAQ:NEO opened at $16.02 on Monday. The company has a market capitalization of $2.07 billion, a P/E ratio of -64.08 and a beta of 1.87. The company’s 50-day moving average is $17.55 and its 200 day moving average is $13.02. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.31 and a current ratio of 3.53. NeoGenomics, Inc. has a fifty-two week low of $7.07 and a fifty-two week high of $20.15.
NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $209.25 million during the quarter, compared to the consensus estimate of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 earnings per share. On average, equities research analysts forecast that NeoGenomics, Inc. will post -0.06 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have commented on NEO shares. Zacks Research lowered shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, October 12th. Craig Hallum reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, July 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 price target on shares of NeoGenomics in a research report on Thursday, October 29th. Finally, TD Cowen lifted their price target on NeoGenomics from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.88.
Check Out Our Latest Research Report on NEO
About NeoGenomics
NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.
See Also
- Five stocks we like better than NeoGenomics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Free Report).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
